Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating inhaled AP01 for progressive pulmonary fibrosis is currently recruiting, with no results yet reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Connective Tissue Disease-associated Interstitial Lung Disease
• Hypersensitivity Pneumonitis
• Interstitial Lung Disease
• Pulmonary Fibrosis
• Rheumatoid Arthritis-associated Interstitial Lung Disease
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• AP01

Snippet

Sponsor: Avalyn Pharma Inc. | Conditions: Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Status: RECRUITING